- Lipoproteins and Cardiovascular Health
- Bone health and osteoporosis research
- Bone health and treatments
- Vitamin D Research Studies
- Menopause: Health Impacts and Treatments
- Parathyroid Disorders and Treatments
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Estrogen and related hormone effects
- Pituitary Gland Disorders and Treatments
- Thyroid Disorders and Treatments
- Thyroid Cancer Diagnosis and Treatment
- Hormonal Regulation and Hypertension
- Ovarian function and disorders
- Cancer, Lipids, and Metabolism
- Adrenal and Paraganglionic Tumors
- Bone and Joint Diseases
- Thyroid and Parathyroid Surgery
- Hemophilia Treatment and Research
- Phytoestrogen effects and research
- Hormonal and reproductive studies
- Ophthalmology and Eye Disorders
- Bone Metabolism and Diseases
- Genetic Syndromes and Imprinting
- Growth Hormone and Insulin-like Growth Factors
- Gestational Diabetes Research and Management
Aristotle University of Thessaloniki
2016-2025
Institute of Urology of the National Academy of Medical Sciences of Ukraine
2023
Papageorgiou General Hospital
2013-2023
V.P. Komisarenko Institute of Endocrinology and Metabolism
2023
Diabetes Australia
2023
European Atherosclerosis Society
2021
AHEPA University Hospital
2021
Hella (Germany)
2020
Ippokrateio General Hospital of Thessaloniki
2011-2019
National and Kapodistrian University of Athens
2017-2019
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of disease (GD). Choice treatment should be based on assessment clinical activity and severity GO. Early referral to specialized centers fundamental for most patients with Risk factors include smoking, thyroid dysfunction, high serum level thyrotropin receptor antibodies, radioactive iodine (RAI) treatment, hypercholesterolemia. In mild active GO, control risk factors, local treatments, selenium (selenium-deficient areas) are...
Graves' orbitopathy (GO) is an autoimmune condition, which associated with poor clinical outcomes including impaired quality of life and socio-economic status. Current evidence suggests that the incidence GO in Europe may be declining, however data on prevalence this disease are sparse. Several variants exist, euthyroid GO, recently listed as a rare (ORPHA466682). The objective was to estimate its Europe, based available literature, consider whether they potentially qualify rare. Recent...